The demand for plastic and aesthetic beauty treatments in Germany has also risen in 2017. This benefits M1 Kliniken AG, which is the number one in the field of beauty medicine in Germany under its “M1 Med Beauty” brand. In 2017 alone, the number of specialist centres in Germany increased from 11 to 17.
M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) has successfully completed the capital increase in accordance with the resolutions passed yesterday and today. The capital increase was oversubscribed several times.
The Management Board of M1 Kliniken AG today resolved to increase the company’s share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 2,2015 with the approval of the Supervisory Board and partially utilizing the authorized capital 2015.
M1 Kliniken AG announces that the company’s Supervisory Board has appointed Dr. Walter von Horstig to the Management Board of the company effective October 1,2017. Together with Patrick Brenske, he will drive the further growth and development of the company.
M1 Kliniken AG will publish its interim report in the course of the day. A strong first half-year is the basis for the company’s continuous growth. M1 Kliniken AG has developed very satisfactorily as a result of increasing demand for plastic and aesthetic beauty treatments due to its price and quality leadership.
M1 Kliniken AG announces the acquisition of a building for a surgery center in Essen, Germany. M1 Kliniken AG has acquired a property with 2,000 square meters in the city center of Essen (Germany) and is planning to build a new surgery center there...
M1 Kliniken AG, ISIN: DE000A0STSQ8, announces its preliminary IFRS result for 2016. In 2016 the Frankfurt Stock Exchange listed M1 Kliniken AG again reported a successful fiscal year. The company increased its sales to €36,546,000.